医学
心肌梗塞
指南
肌钙蛋白
优势比
危险分层
内科学
置信区间
队列研究
队列
诊断优势比
心脏病学
急诊医学
心脏外科
肌钙蛋白I
前瞻性队列研究
病理
作者
Selene Martinez-Perez,Judith A. R. van Waes,Lisette M. Vernooij,Brian H. Cuthbertson,W. Scott Beattie,Duminda N. Wijeysundera,Wilton A. van Klei
标识
DOI:10.1016/j.bja.2023.12.019
摘要
Abstract
Background
Clinical presentation of postoperative myocardial infarction (POMI) is often silent. Several international guidelines recommend routine troponin surveillance in patients at risk. We compared how these different guidelines select patients for surveillance after noncardiac surgery with our established risk stratification model. Methods
We used outcome data from two prospective studies: Measurement of Exercise Tolerance before Surgery (METS) and Troponin Elevation After Major non-cardiac Surgery (TEAMS). We compared the major American, Canadian, and European guideline recommendations for troponin surveillance with our established risk stratification model. For each guideline and model, we quantified the number of patients requiring monitoring, % POMI detected, sensitivity, specificity, diagnostic odds ratio, and number needed to screen (NNS). Results
METS and TEAMS contributed 2350 patients, of whom 319 (14%) had myocardial injury, 61 (2.5%) developed POMI, and 14 (0.6%) died. Our risk stratification model selected fewer patients for troponin monitoring (20%), compared with the Canadian (78%) and European (79%) guidelines. The sensitivity to detect POMI was highest with the Canadian and European guidelines (0.85; 95% confidence interval [CI] 0.74–0.92). Specificity was highest using the American guidelines (0.91; 95% CI 0.90–0.92). Our risk stratification model had the best diagnostic odds ratio (2.5; 95% CI 1.4–4.2) and a lower NNS (21 vs 35) compared with the guidelines. Conclusions
Most postoperative myocardial infarctions were detected by the Canadian and European guidelines but at the cost of low specificity and a higher number of patients undergoing screening. Patient selection based on our risk stratification model was optimal.
科研通智能强力驱动
Strongly Powered by AbleSci AI